missing translation for 'onlineSavingsMsg'
Learn More
Learn More
R&D Systems™ Recombinant Human IL-18/IL-1F4 Protein
Extensive quality control produces industry leading bioactivity and lot-to-lot consistency that instills confidence in results and ensures reproducibility. Applications: Bioactivity
Brand: R&D Systems™ 9124-IL-010/CF
This item is not returnable.
View return policy
Description
The Recombinant Human IL-18/IL-1F4 Protein is derived from E. coli. The Recombinant Human IL-18/IL-1F4 Protein has been validated for the following applications: Bioactivity.Specifications
| Q14116 | |
| 3606 | |
| 10 μg | |
| Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70° C as supplied. 1 month, 2 to 8° C under sterile conditions after reconstitution. 3 months, -20 to -70° C under sterile conditions after reconstitution. | |
| Iboctadekin, IFN-gamma-inducing factor, IGIF, IGIFIL-1 gamma, IL18, IL-18MGC12320, IL-1F4, IL1F4iboctadekin, IL-1g, Interferon gamma-inducing factor, interleukin 18 (interferon-gamma-inducing factor), Interleukin-1 gamma, interleukin-18 | |
| IL18 | |
| Unconjugated | |
| Recombinant | |
| >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie™ Blue Staining |
| Bioactivity | |
| Observed M.W.: 19kDa, reducing conditions, Theoretical M.W.: 18kDa | |
| E. coli-derived human IL-18/IL-1F4 protein Tyr37-Asp193 | |
| <0.10 EU per 1μg of the protein by the LAL method. | |
| IL-18/IL-1F4 | |
| Measured by its ability to induce IFN-gamma secretion by KG-1 human acute myelogenous leukemia cells in the presence of TNF-alpha . The ED50 for this effect is typically 1.5-9ng/mL. | |
| Human | |
| E. coli-derived Tyr37-Asp193 |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction